240 related articles for article (PubMed ID: 20980590)
21. Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial.
Sánchez-Reyes L; Fanghänel G; Yamamoto J; Martínez-Rivas L; Campos-Franco E; Berber A
Clin Ther; 2004 Sep; 26(9):1427-35. PubMed ID: 15531005
[TBL] [Abstract][Full Text] [Related]
22. Anti-obesity drugs: what does sibutramine offer? An analysis of its potential contribution to obesity treatment.
Van Gaal LF; Wauters MA; De Leeuw IH
Exp Clin Endocrinol Diabetes; 1998; 106 Suppl 2():35-40. PubMed ID: 9792480
[TBL] [Abstract][Full Text] [Related]
23. Reversal of sibutramine-induced anorexia with a selective 5-HT(2C) receptor antagonist.
Higgs S; Cooper AJ; Barnes NM
Psychopharmacology (Berl); 2011 Apr; 214(4):941-7. PubMed ID: 21140257
[TBL] [Abstract][Full Text] [Related]
24. Studies on the role of serotonin receptor subtypes in the effect of sibutramine in various feeding paradigms in rats.
Grignaschi G; Fanelli E; Scagnol I; Samanin R
Br J Pharmacol; 1999 Jul; 127(5):1190-4. PubMed ID: 10455265
[TBL] [Abstract][Full Text] [Related]
25. Sibutramine. A review of its contribution to the management of obesity.
McNeely W; Goa KL
Drugs; 1998 Dec; 56(6):1093-124. PubMed ID: 9878996
[TBL] [Abstract][Full Text] [Related]
26. The effect of sibutramine on energy expenditure and appetite during chronic treatment without dietary restriction.
Hansen DL; Toubro S; Stock MJ; Macdonald IA; Astrup A
Int J Obes Relat Metab Disord; 1999 Oct; 23(10):1016-24. PubMed ID: 10557021
[TBL] [Abstract][Full Text] [Related]
27. Systemic treatment with D-fenfluramine, but not sibutramine, blocks cue-induced reinstatement of food-seeking behavior in the rat.
Pratt WE; Ford RT
Neurosci Lett; 2013 Nov; 556():232-7. PubMed ID: 24157852
[TBL] [Abstract][Full Text] [Related]
28. Regional brain response to visual food cues is a marker of satiety that predicts food choice.
Mehta S; Melhorn SJ; Smeraglio A; Tyagi V; Grabowski T; Schwartz MW; Schur EA
Am J Clin Nutr; 2012 Nov; 96(5):989-99. PubMed ID: 22990034
[TBL] [Abstract][Full Text] [Related]
29. Who will lose weight on sibutramine and orlistat? Psychological correlates for treatment success.
Elfhag K; Finer N; Rössner S
Diabetes Obes Metab; 2008 Jun; 10(6):498-505. PubMed ID: 17593239
[TBL] [Abstract][Full Text] [Related]
30. Changes in differential functional magnetic resonance signals in the rodent brain elicited by mixed-nutrient or protein-enriched meals.
Min DK; Tuor UI; Koopmans HS; Chelikani PK
Gastroenterology; 2011 Nov; 141(5):1832-41. PubMed ID: 21802388
[TBL] [Abstract][Full Text] [Related]
31. Sibutramine decreases body weight gain and increases energy expenditure in obese Zucker rats without changes in NPY and orexins.
Casado A; Rodríguez VM; Portillo MP; Macarulla MT; Abecia LC; Echevarría E; Casis L
Nutr Neurosci; 2003 Apr; 6(2):103-11. PubMed ID: 12722985
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and tolerability of sibutramine in obese patients: a dose-ranging study.
Hanotin C; Thomas F; Jones SP; Leutenegger E; Drouin P
Int J Obes Relat Metab Disord; 1998 Jan; 22(1):32-8. PubMed ID: 9481597
[TBL] [Abstract][Full Text] [Related]
33. Oxytocin reduces the functional connectivity between brain regions involved in eating behavior in men with overweight and obesity.
Kerem L; Hadjikhani N; Holsen L; Lawson EA; Plessow F
Int J Obes (Lond); 2020 May; 44(5):980-989. PubMed ID: 31740723
[TBL] [Abstract][Full Text] [Related]
34. Neural responses to visual food stimuli after a normal vs. higher protein breakfast in breakfast-skipping teens: a pilot fMRI study.
Leidy HJ; Lepping RJ; Savage CR; Harris CT
Obesity (Silver Spring); 2011 Oct; 19(10):2019-25. PubMed ID: 21546927
[TBL] [Abstract][Full Text] [Related]
35. The effect of sibutramine intake on resting and exercise physiological responses.
Rotstein A; Inbar O; Vaisman N
Ann Nutr Metab; 2008; 52(1):17-23. PubMed ID: 18230966
[TBL] [Abstract][Full Text] [Related]
36. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity.
Blundell J; Finlayson G; Axelsen M; Flint A; Gibbons C; Kvist T; Hjerpsted JB
Diabetes Obes Metab; 2017 Sep; 19(9):1242-1251. PubMed ID: 28266779
[TBL] [Abstract][Full Text] [Related]
37. [Pharmacological therapy of obesity].
Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
[TBL] [Abstract][Full Text] [Related]
38. Sibutramine: a review of the pharmacology of a novel anti-obesity agent.
Stock MJ
Int J Obes Relat Metab Disord; 1997 Mar; 21 Suppl 1():S25-9. PubMed ID: 9130038
[TBL] [Abstract][Full Text] [Related]
39. Striatal opioid peptide gene expression differentially tracks short-term satiety but does not vary with negative energy balance in a manner opposite to hypothalamic NPY.
Will MJ; Vanderheyden WM; Kelley AE
Am J Physiol Regul Integr Comp Physiol; 2007 Jan; 292(1):R217-26. PubMed ID: 16931647
[TBL] [Abstract][Full Text] [Related]
40. Effects of sibutramine on body weight and serum lipids: a double-blind, randomized, placebo-controlled study in 322 overweight and obese patients with dyslipidemia.
Dujovne CA; Zavoral JH; Rowe E; Mendel CM;
Am Heart J; 2001 Sep; 142(3):489-97. PubMed ID: 11526363
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
